The first NSCLC biomarker was proposed by Boutros et al.[17] and contains the following genes: STX1A, HIF1A, CCT3, HLA-DPB1, RNF5, and MAFK. The second NSCLC biomarker was proposed by Chen et al.[18] and contains the genes DUSP6, MMD, STAT1, ERBB3, and LCK. Therefore, it is of clinical interest to compare their performance. This evidence concerns the gene MMD and non-small cell lung carcinoma.